Drug intelligence / Profile preview

D3L-003

Development stage: Preclinical
Lead developer: D3 Bio
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

D3L-003 is a bispecific antibody developed by D3 Bio (Wuxi) Co. Ltd for the treatment of neoplasms, specifically targeting solid tumors. As a bispecific antibody, it is designed to simultaneously bind two different antigens or epitopes, potentially enhancing anti-tumor efficacy through dual targeting mechanisms. The drug is currently in preclinical development and has not yet entered clinical trials or received regulatory approval[1].

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)CD47 (Cluster of Differentiation 47)

Beyond the preview

Go deeper on D3L-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D3L-003.

Explore the full profile